Travere Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Travere Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Travere Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $291M, a 0.93% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $291M -$2.72M -0.93% Dec 31, 2023 10-K 2024-02-20
Q4 2022 $293M +$95.1M +48% Dec 31, 2022 10-K 2024-02-20
Q4 2021 $198M +$50.5M +34.1% Dec 31, 2021 10-K 2023-02-23
Q4 2020 $148M +$63.1M +74.4% Dec 31, 2020 10-K 2022-02-24
Q4 2019 $84.7M +$48.6M +134% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $36.2M +$8.57M +31% Dec 31, 2018 10-K 2020-02-24
Q4 2017 $27.6M +$12M +77.3% Dec 31, 2017 10-K 2019-02-26
Q4 2016 $15.6M +$8.6M +123% Dec 31, 2016 10-K/A 2018-07-06
Q4 2015 $6.98M -$29M -80.6% Dec 31, 2015 10-K 2017-03-01
Q4 2014 $36M +$24M +199% Dec 31, 2014 10-K 2016-02-26
Q4 2013 $12M +$10.1M +532% Dec 31, 2013 10-K/A 2015-07-09
Q4 2012 $1.91M Dec 31, 2012 10-K/A 2015-07-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.